Role of adenosine triphosphate-sensitive potassium channel inhibition in shock states: physiology and clinical implications.
Shock states are associated with an impaired tissue oxygen supply-demand relationship and perturbations within the microcirculation, leading to global tissue hypoxia, finally resulting in multiple-organ failure or even death. Two of the most frequent causes of shock are acute hemorrhage and sepsis. Although the origin and the pathophysiology of hemorrhagic and septic shock are basically different, the involvement of adenosine triphosphate-sensitive potassium (KATP) channels, as an important regulator of vascular smooth muscles tone, plays a pivotal role under both conditions. Because the excessive activation of vascular KATP channels is a major cause of arterial hypotension and vascular hyporesponsiveness to catecholamines, the pharmacological inhibition of KATP channels may represent a goal-directed therapeutic option to stabilize the hemodynamic situation in shock states. Despite promising results of preclinical studies, the efficacy of this innovative therapeutic approach remains to be confirmed in the clinical setting. The differences in the species, the comorbidity, and the difficulty in determining the exact onset of shock in clinical practice and, thus, any duration-related alterations in vascular responses and KATP channel activation may explain the discrepancy between the results obtained from experimental and clinical studies. Currently, two of the most relevant problems related to effective KATP blockade in shock states are represented by (1) the dose itself (benefit-risk ratio) and (2) the route of administration (oral vs. i.v.). This review article critically elucidates the published in vivo studies on the role of KATP channel inhibition in both described shock forms and discusses the advantages and the potential pitfalls related to the treatment of human shock states.
Lange
Matthias
M
Department of Anesthesiology and Intensive Care, University of Muenster, Germany. lange-m@anit.uni-muenster.de
Morelli
Andrea
A
Ertmer
Christian
C
Bröking
Katrin
K
Rehberg
Sebastian
S
Van Aken
Hugo
H
Traber
Daniel L
DL
Westphal
Martin
M
D000255:Adenosine Triphosphate / Q000378:metabolism*; D000818:Animals; D006470:Hemorrhage / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control; D006801:Humans; D008954:Models, Biological; D026902:Potassium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use; D015221:Potassium Channels / Q000378:metabolism / Q000502:physiology*; D012769:Shock / Q000378:metabolism / Q000503:physiopathology* / Q000517:prevention & control; D012772:Shock, Septic / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control
D026902:Potassium Channel Blockers; D015221:Potassium Channels; D000255:Adenosine Triphosphate